French pharmaceutical company Servier and US-based Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) announced a strategic global licensing agreement for BDTX-4933 on March 19, 2025. This collaboration aims to advance the development of BDTX-4933, a potential best-in-class targeted therapy for solid tumors.
Drug Profile
BDTX-4933 is uniquely designed by Black Diamond to target RAS and RAF alterations in solid tumors. It is currently in Phase 1 development and represents a novel approach to treating cancers driven by these genetic mutations.
Financial Terms and Development
Under the agreement, Servier will lead the development and worldwide commercialization of BDTX-4933 across multiple indications, including non-small cell lung cancer (NSCLC) and other solid tumors. Black Diamond Therapeutics will receive an upfront payment of USD 70 million and is eligible for up to USD 710 million in development and commercial sales milestone payments, along with tiered royalties based on global net sales.
Strategic Rationale
This partnership leverages Servier’s expertise in oncology and Black Diamond’s innovative drug discovery platform. The combination positions BDTX-4933 for accelerated development, with the potential to address significant unmet needs in solid tumor treatment.-Fineline Info & Tech
Leave a Reply